High dose folic acid during pregnancy and the risk of autism; The birth order bias: A nested case-control study.


Journal

Reproductive toxicology (Elmsford, N.Y.)
ISSN: 1873-1708
Titre abrégé: Reprod Toxicol
Pays: United States
ID NLM: 8803591

Informations de publication

Date de publication:
10 2019
Historique:
received: 22 05 2019
revised: 23 07 2019
accepted: 30 07 2019
pubmed: 4 8 2019
medline: 12 5 2020
entrez: 4 8 2019
Statut: ppublish

Résumé

To examine whether there is an association between the cumulative dose of folic acid (FA) purchased by mothers, and risk of autistic spectrum disorders (ASD) in their progeny. We identified 2009 singletons who received an ASD diagnosis from a cohort of 480,526 children born in a large health organization in Israel from 2000 through 2013. ASD patients were individually matched to ASD-free children (n = 19,886). Median cumulative daily doses of supplemented FA during the 12-month period prior to the end of pregnancy (from dispensing records) were compared using conditional logistic regression models. Children with ASD were more likely to be first-born, and birth-order was significantly associated with FA use. In multivariable analysis, there were no statistically significant differences in the cumulative dose of FA between the groups. Birth order effects need to be accounted for in analyses aiming to decipher the associations between gestational FA use and developmental outcomes.

Identifiants

pubmed: 31376478
pii: S0890-6238(19)30262-X
doi: 10.1016/j.reprotox.2019.07.083
pii:
doi:

Substances chimiques

Folic Acid 935E97BOY8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-177

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Sarah Sharman Moser (S)

Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel. Electronic address: moser_sa@mac.org.il.

Michael Davidovitch (M)

Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel.

Ran S Rotem (RS)

Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel; Harvard T.H. Chan School of Public Health, USA.

Gabriel Chodick (G)

Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Varda Shalev (V)

Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Gideon Koren (G)

Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH